QGEN Collaborates With McGill University Centre: Stock to Gain?
In This Article:
QIAGEN N.V. QGEN recently collaborated with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further advance microbiome sciences and focus on key areas such as DNA extraction from low microbial biomass samples and anaerobic culturing protocols.
The latest partnership aims to strengthen QIAGEN’s microbiome research efforts while supporting innovation at the McGill Centre.
QGEN Stock’s Trend Following the News
Subsequent to the news, the share price of QGEN remained unchanged at $43.23 in after-market trading yesterday. The company is gaining synergies from its collaboration in the microbiome research space. Earlier this year, QGEN partnered with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. Henceforth, we expect the latest partnership with McGill Centre to motivate market sentiment in favor of QGEN in the coming days.
QIAGEN currently has a market capitalization of $9.83 billion. The company delivered an average earnings surprise of 2.6% in the trailing four quarters.
Details of the Collaboration
The company will support the McGill Centre with reagents for research across a variety of microbiology and genomic processing workflows and contribute to joint research projects, which will demonstrate the suitability of QIAGEN products for microbiome science. The collaboration will also enable the McGill Centre to train the next generation of scientists better and make microbiome research accessible to a wider range of scientific domains.
QIAGEN products will be used in the McGill Centre's experimental platforms. The centre will also function as a beta-testing site for developing new QIAGEN products for microbiome applications, and refining and optimizing these for broader applications in the scientific community.
The center aims to integrate and synergize microbiome research activities by offering services through two distinct yet complementary experimental platforms — Gnotobiotic Animal Research and Microbial Services.
Significance of QIAGEN’s Collaboration
Microbiome research aims to explore the relationships between microorganisms such as bacteria, fungi and viruses, and their hosts. It can help better understand the microbiome’s impact on health, disease, and microbial ecological processes to develop novel diagnostic and therapeutic strategies.
The latest collaboration is expected to strengthen QIAGEN’s presence in microbiome research space across North America, which represents a $1.8 billion market. It will also help gain a deeper understanding of the needs of the scientific community for studying the function of vast microbial ecosystems. The collaboration aims to enhance QIAGEN’s ability to develop new microbiome solutions based on customer feedback and support the scientific community in uncovering new insights into the microbiome’s impact on health and disease.
